Mcneil Ab

Invent Medic Sweden Ab

Enzymatica Ab

Kipax Ab

Elisabeth Sthengel

Line Irene Andersen

Mark Peter Warchol

Kristina Thyresson

Lars Lindgren

Ulrika Andersson

Folke Morén

Karin Bryder

Sven-Börje Andersson

Folke Moren

Sven-Boerje Andersson

Fredrik Lindberg

See Man Ngo

A vaginal device and method of preventing urinary incontinence is disclosed. The device includes a longitudinal portion having a geometrical centre line, a first end and a second end, the first end being the innermost of the vaginal device during use, at least one supporting portion protruding from the longitudinal portion at the first end, the at least one supporting portion being configured to support against the urethra, through the vaginal wall, at a site located adjacent the maximal urethral pressure point, and a reference member protruding from the longitudinal portion at the second end, wherein the reference member during use is fixated against the vaginal introitus, holding the vaginal device securely fixated inside of the vagina and ensuring the at least one supporting portion is arranged at the intended site. The device further includes a section of the longitudinal portion, arranged between the supporting portion and the reference member, that has a decreasing cross-section towards the reference member and/or has at least one notch, groove and/or slot in an outer surface along an axial direction of the section.

Vaginal device

Provided are liquid pharmaceutical formulations comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tof nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably accomplished by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. Methods for manufacturing the formulation is also disclosed, as are uses of the formulation in therapy, such as therapy for treating addiction to tobacco.

Formulation and use thereof

A liquid pharmaceutical formulation comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tof nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. A method for manufacturing said formulation. Use of said formulation in therapy, such as therapy for treating addiction to tobacco.

Growing community of inventors

Helsingborg, Sweden

Elisabeth Sthengel